

Claris Lifesciences Limited
 Regd. Office: Claris Corporate Headquarters, Nr. Parimal Railway Crossing, Ellisbridge, Ahmedabad – 380006
 website : www.clarislifesciences.com, e-mail : investorservices.corp@clarislifesciences.com

Unaudited Financial Results for the Quarter and Nine Months ended September 30, 2013

(Rs. In Lacs except EPS and Shares)

Particulars	Consolidated						Standalone					
	Quarter Ended			Year to Date		Year ended	Quarter Ended			Year to date		Year ended
	30th Sep 2013	30th June 2013	30th Sep 2012	30th Sep 2013	30th Sep 2012	31st December 2012	30th Sep 2013	30th June 2013	30th Sep 2012	30th Sep 2013	30th Sep 2012	31st December 2012
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
PART II												
A PARTICULARS OF SHAREHOLDING												
1. Public Shareholding												
- No. of shares	25,392,554	25,392,554	24,212,434	25,392,554	24,212,434	24,212,434	25,392,554	25,392,554	24,212,434	25,392,554	24,212,434	24,212,434
- Percentage of shareholding	39.79%	39.79%	37.94%	39.79%	37.94%	37.94%	39.79%	39.79%	37.94%	39.79%	37.94%	37.94%
2. Promoters and Promoter group shareholding												
a) Pledged/Encumbered												
- Number of shares	6,834,000	6,834,000	7,954,930	6,834,000	7,954,930	7,724,000	6,834,000	6,834,000	7,954,930	6,834,000	7,954,930	7,724,000
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	17.79%	17.79%	20.08%	17.79%	20.08%	19.50%	17.79%	17.79%	20.08%	17.79%	20.08%	19.50%
- Percentage of shares (as a % of the total share capital of the Company)	10.71%	10.71%	12.46%	10.71%	12.46%	12.10%	10.71%	10.71%	12.46%	10.71%	12.46%	12.10%
b) Non-encumbered												
- Number of Shares	31,591,211	31,591,211	31,650,401	31,591,211	31,650,401	31,881,331	31,591,211	31,591,211	31,650,401	31,591,211	31,650,401	31,881,331
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	82.21%	82.21%	79.92%	82.21%	79.92%	80.50%	82.21%	82.21%	79.92%	82.21%	79.92%	80.50%
- Percentage of shares (as a % of the total share capital of the Company)	49.50%	49.50%	49.59%	49.50%	49.59%	49.96%	49.50%	49.50%	49.59%	49.50%	49.59%	49.96%
B INVESTOR COMPLAINTS												
Pending at the beginning of the quarter												
Received during the quarter												
Disposed of during the quarter												
Remaining unresolved at the end of the												

Notes:

- 1 The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 13th November, 2013
- 2 The Company has only one reportable business segment, namely, Drugs & Pharmaceuticals.
- 3 On 31st July 2013, pursuant to agreements with Otsuka Pharmaceutical Factory, Inc., Japan Otsuka and Mitsui & Co. Ltd., Japan (Mitsui), the Company has transferred its Infusion Business to Claris Otsuka Limited on a slump sale basis. Post transfer of business, the Company holds 20% of equity share capital of Claris Otsuka Limited. The Company operates under a single business segment, and in view of common employees, marketing expenses, logistics and distribution arrangements and general corporate overheads, which are not separately identifiable for identified products of the infusion business which has been transferred; the Company is unable to determine the income and expenses clearly attributable to the discontinuing operation. Under the facts and circumstances, the Company is unable to disclose separately the profit from the continuing and discontinuing operations, tax expense of discontinuing operations and profit from discontinuing operations after tax.

Necessary disclosures pertaining to the discontinuing operations and reorganisation of the business are as under: -

(Rs. in Lacs)

Particulars	Quarter Ended			Year to Date		
	30th Sept 2013	30th June 2013	30th Sep 2012	30th Sept 2013	30th Sep 2012	31st Dec 2012
Revenue	1,867.52	11,953.21	11,387.01	22,055.73	30,471.56	42,854.56

In view of the transfer of the infusion business, the figures for the quarter and nine months ended 30th September, 2013 do not include corresponding figures pertaining to the discontinued operations for the period from 1st August, 2013 to 30th September, 2013 and hence the same are not comparable with the figures for the previous corresponding quarters and period.

- 4 The exceptional item for the quarter and nine months ended 30th September, 2013 of Rs. 1,505.98 Lacs pertains to profit on transfer of Infusion Business to Claris Otsuka Limited on a slump sale basis as stated in note no. 3 above and the figures for the year ended 31st December, 2012 of Rs. (45.10) Lacs pertains to provision for diminution in the value of long term investments in PT Claris Lifesciences Indonesia, a wholly owned subsidiary.
- 5 The figures for the previous year / period have been regrouped / rearranged wherever necessary.

For Claris Lifesciences Limited

Place : Ahmedabad
Date 13th November , 2013

Arjun S. Handa
Managing Director & CEO